Literature DB >> 21622630

ApoA-I deficiency in mice is associated with redistribution of apoA-II and aggravated AApoAII amyloidosis.

Yaoyong Wang1, Jinko Sawashita, Jinze Qian, Beiru Zhang, Xiaoying Fu, Geng Tian, Lei Chen, Masayuki Mori, Keiichi Higuchi.   

Abstract

Apolipoprotein A-II (apoA-II) is the second major apolipoprotein following apolipoprotein A-I (apoA-I) in HDL. ApoA-II has multiple physiological functions and can form senile amyloid fibrils (AApoAII) in mice. Most circulating apoA-II is present in lipoprotein A-I/A-II. To study the influence of apoA-I on apoA-II and AApoAII amyloidosis, apoA-I-deficient (C57BL/6J.Apoa1⁻/⁻) mice were used. Apoa1⁻/⁻ mice showed the expected significant reduction in total cholesterol (TC), HDL cholesterol (HDL-C), and triglyceride (TG) plasma levels. Unexpectedly, we found that apoA-I deficiency led to redistribution of apoA-II in HDL and an age-related increase in apoA-II levels, accompanied by larger HDL particle size and an age-related increase in TC, HDL-C, and TG. Aggravated AApoAII amyloidosis was induced in Apoa1⁻/⁻ mice systemically, especially in the heart. These results indicate that apoA-I plays key roles in maintaining apoA-II distribution and HDL particle size. Furthermore, apoA-II redistribution may be the main reason for aggravated AApoAII amyloidosis in Apoa1⁻/⁻ mice. These results may shed new light on the relationship between apoA-I and apoA-II as well as provide new information concerning amyloidosis mechanism and therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622630      PMCID: PMC3133974          DOI: 10.1194/jlr.M013235

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  43 in total

1.  A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene.

Authors:  M D Benson; J J Liepnieks; M Yazaki; T Yamashita; K Hamidi Asl; B Guenther; B Kluve-Beckerman
Journal:  Genomics       Date:  2001-03-15       Impact factor: 5.736

Review 2.  Animal lipoproteins: chemistry, structure, and comparative aspects.

Authors:  M J Chapman
Journal:  J Lipid Res       Date:  1980-09       Impact factor: 5.922

3.  Activation of lecithin:cholesterol acyltransferase by HDL ApoA-I central helices.

Authors:  Mary G Sorci-Thomas; Shaila Bhat; Michael J Thomas
Journal:  Clin Lipidol       Date:  2009-02

Review 4.  Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management.

Authors:  Walid Hassan; Hani Al-Sergani; Walid Mourad; Rashed Tabbaa
Journal:  Tex Heart Inst J       Date:  2005

5.  Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.

Authors:  Vicent Ribas; José Luis Sánchez-Quesada; Rosa Antón; Mercedes Camacho; Josep Julve; Joan Carles Escolà-Gil; Luís Vila; Jordi Ordóñez-Llanos; Francisco Blanco-Vaca
Journal:  Circ Res       Date:  2004-09-23       Impact factor: 17.367

6.  Tissue distribution, biochemical properties, and transmission of mouse type A AApoAII amyloid fibrils.

Authors:  Tatsumi Korenaga; Xiaoying Fu; Yanming Xing; Takatoshi Matsusita; Kazunao Kuramoto; Seigo Syumiya; Kazuhiro Hasegawa; Hironobu Naiki; Masaki Ueno; Tokuhiro Ishihara; Masanori Hosokawa; Masayuki Mori; Keiichi Higuchi
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

7.  Transmissibility of mouse AApoAII amyloid fibrils: inactivation by physical and chemical methods.

Authors:  Huanyu Zhang; Jinko Sawashita; Xiaoying Fu; Tatsumi Korenaga; Jingmin Yan; Masayuki Mori; Keiichi Higuchi
Journal:  FASEB J       Date:  2006-03-20       Impact factor: 5.191

8.  Protection against atherogenesis in mice mediated by human apolipoprotein A-IV.

Authors:  N Duverger; G Tremp; J M Caillaud; F Emmanuel; G Castro; J C Fruchart; A Steinmetz; P Denèfle
Journal:  Science       Date:  1996-08-16       Impact factor: 47.728

9.  Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia.

Authors:  P Alaupovic; C Knight-Gibson; C S Wang; D Downs; E Koren; H B Brewer; R E Gregg
Journal:  J Lipid Res       Date:  1991-01       Impact factor: 5.922

10.  Novel N-terminal mutation of human apolipoprotein A-I reduces self-association and impairs LCAT activation.

Authors:  Paul M M Weers; Arti B Patel; Leon C-P Wan; Emmanuel Guigard; Cyril M Kay; Anouar Hafiane; Ruth McPherson; Yves L Marcel; Robert S Kiss
Journal:  J Lipid Res       Date:  2010-09-30       Impact factor: 5.922

View more
  11 in total

1.  Cholesterol-Independent Suppression of Lymphocyte Activation, Autoimmunity, and Glomerulonephritis by Apolipoprotein A-I in Normocholesterolemic Lupus-Prone Mice.

Authors:  Leland L Black; Roshni Srivastava; Trenton R Schoeb; Ray D Moore; Stephen Barnes; Janusz H Kabarowski
Journal:  J Immunol       Date:  2015-10-14       Impact factor: 5.422

2.  Apolipoprotein A-1 regulates osteoblast and lipoblast precursor cells in mice.

Authors:  Harry C Blair; Elena Kalyvioti; Nicholaos I Papachristou; Irina L Tourkova; Spryros A Syggelos; Despina Deligianni; Malvina G Orkoula; Christos G Kontoyannis; Eleni A Karavia; Kyriakos E Kypreos; Dionysios J Papachristou
Journal:  Lab Invest       Date:  2016-04-18       Impact factor: 5.662

3.  Disrupting the DREAM transcriptional repressor complex induces apolipoprotein overexpression and systemic amyloidosis in mice.

Authors:  Pirunthan Perampalam; Haider M Hassan; Grace E Lilly; Daniel T Passos; Joseph Torchia; Patti K Kiser; Andrea Bozovic; Vathany Kulasingam; Frederick A Dick
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

4.  High yield expression and purification of recombinant human apolipoprotein A-II in Escherichia coli.

Authors:  Loren E Smith; Jun Yang; Leah Goodman; Xinqi Huang; Rong Huang; James Dressman; Jamie Morris; R A Gangani D Silva; W Sean Davidson; Giorgio Cavigiolio
Journal:  J Lipid Res       Date:  2012-05-25       Impact factor: 5.922

5.  Alginic acid cell entrapment: a novel method for measuring in vivo macrophage cholesterol homeostasis.

Authors:  Timothy J Sontag; Bijoy Chellan; Clarissa V Bhanvadia; Godfrey S Getz; Catherine A Reardon
Journal:  J Lipid Res       Date:  2014-12-01       Impact factor: 5.922

6.  C-terminal sequence of amyloid-resistant type F apolipoprotein A-II inhibits amyloid fibril formation of apolipoprotein A-II in mice.

Authors:  Jinko Sawashita; Beiru Zhang; Kazuhiro Hasegawa; Masayuki Mori; Hironobu Naiki; Fuyuki Kametani; Keiichi Higuchi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-09       Impact factor: 11.205

7.  Caloric restriction reduces the systemic progression of mouse AApoAII amyloidosis.

Authors:  Lin Li; Jinko Sawashita; Xin Ding; Mu Yang; Zhe Xu; Hiroki Miyahara; Masayuki Mori; Keiichi Higuchi
Journal:  PLoS One       Date:  2017-02-22       Impact factor: 3.240

8.  Polymorphisms of mouse apolipoprotein A-II alter its physical and functional nature.

Authors:  Timothy J Sontag; Catherine A Reardon
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

9.  Apolipoprotein A-II induces acute-phase response associated AA amyloidosis in mice through conformational changes of plasma lipoprotein structure.

Authors:  Mu Yang; Yingye Liu; Jian Dai; Lin Li; Xin Ding; Zhe Xu; Masayuki Mori; Hiroki Miyahara; Jinko Sawashita; Keiichi Higuchi
Journal:  Sci Rep       Date:  2018-04-04       Impact factor: 4.379

10.  Accelerated pre-senile systemic amyloidosis in PACAP knockout mice - a protective role of PACAP in age-related degenerative processes.

Authors:  Dora Reglodi; Adel Jungling; Rémi Longuespée; Joerg Kriegsmann; Rita Casadonte; Mark Kriegsmann; Tamas Juhasz; Sebastian Bardosi; Andrea Tamas; Balazs Daniel Fulop; Krisztina Kovacs; Zsuzsanna Nagy; Jason Sparks; Attila Miseta; Gabriel Mazzucchelli; Hitoshi Hashimoto; Attila Bardosi
Journal:  J Pathol       Date:  2018-07-04       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.